<DOC>
	<DOCNO>NCT00946699</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability intravenously administer MEDI-551 escalate single dos adult subject Scleroderma</brief_summary>
	<brief_title>A Study Safety Tolerability MEDI-551 Scleroderma</brief_title>
	<detailed_description>To evaluate safety tolerability escalate single IV dose MEDI-551 adult subject scleroderma least moderate skin thicken area suitable repeat biopsy .</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<criteria>Male female subject Age ≥ 18 year age time screen Written informed consent HIPAA authorization ( applies cover entity USA ) obtain subject/legal representative prior performing protocolrelated procedure , include screen evaluation Must fulfill American Rheumatism Association ( American College Rheumatology ) preliminary classification criterion systemic sclerosis Has least moderate skin thickening ( score least 2 mRTSS ) least one area suitable repeat biopsy , arm , leg , trunk Females childbearing potential , unless surgically sterile ( ie , bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) , sterile male partner , least 2 year post menopause , practice abstinence , must use 2 effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , use condom spermicide sexual partner ) , screen , must agree continue use precaution Early Discontinuation Visit/End Study ( Day 85 , singledose cohort ) ; cessation birth control occur 5 halflives postcessation MEDI551 , 5 halflives estimate 75 day Men , unless surgically sterile , must use 2 effective method birth control female partner must agree continue use contraceptive precaution Day 1 Early Discontinuation Visit/End Study ( Day 85 , singledose cohort ) 5 halflives postcessation MEDI551 , 5 halflives estimate 75 day Ability complete study period , include followup period Day 85 Willingness forego form experimental treatment study ( Day 1 Early Discontinuation Visit/End Study Day 85 , singledose cohort ) History allergic reaction component investigational product History coagulation disorder opinion investigator would contraindicate skin biopsy Has body weight ≥ 120 kg &lt; 40 kg Has Bcell count peripheral blood &lt; 50 % low limit normal ( LLN ) screen Forced vital capacity ( FVC ) &lt; 55 % predict , diffuse capacity carbon monoxide ( DLCO ) &lt; 40 % predict , pulmonary hypertension require treatment endothelin receptor antagonists prostacyclin analogue Scleroderma renal crisis within last year , medically significant malabsorption Receipt Bcelldepleting biologic therapy time , rituximab Receipt leflunomide &gt; 20 mg/day within 6 month prior randomization study Receipt follow concomitant medication within 21 day prior randomization study : Prednisone &gt; 30 mg/day &gt; 0.5 mg/kg Cyclophosphamide Systemic cyclosporine Thalidomide Hydroxychloroquine &gt; 600 mg/day Mycophenolate mofetil &gt; 3 g/day Methotrexate &gt; 25 mg/week Azathioprine &gt; 3 mg/kg/day Concomitant methotrexate leflunomide Any investigational drug therapy nonBcelldepleting biologic therapy ( within 5 halflives ingestion , whichever longer ) Change stand daily dosage follow within 21 day randomization study : Antimalarials Mycophenolate mofetil Methotrexate Leflunomide Azathioprine Systemic corticosteroid At screen blood test ( within 21 day prior randomization study ) , follow : Aspartate aminotransferase ( AST ) &gt; 1.5 × upper limit normal range ( ULN ) unless due document myositis Alanine aminotransferase ( ALT ) &gt; 1.5 × ULN unless due document myositis Total bilirubin &gt; ULN , unless know Gilbert 's disease Total immunoglobin &lt; 500 mg/dl Creatinine &gt; 2.5 mg/dL Neutrophils &lt; 1,500/mm3 Platelet count &lt; 75,000/mm3 Hemoglobin ( Hgb ) &lt; 8 g/dL Hemoglobin A1c ( HbA1c ) &gt; 8 % screening ( diabetic subject ) Positive serum βHCG ( pregnancy test ) Lactating woman Herpes zoster infection within 3 month randomization A history severe viral infection judge investigator , include severe infection either cytomegalovirus herpes family disseminate herpes , herpes encephalitis , ophthalmic herpes At screening , positive test active hepatitis A , hepatitis B surface antigen ( HbsAg ) , Hepatitis B core antibody ( HbcAb ) hepatitis C serology , human immunodeficiency virus1 2 ( HIV1/2 ) . False positive test include . Deep space/tissue infection ( eg , fasciitis , abscess , osteomyelitis , infect joint replacement ) within 1 year randomization study Any opportunistic infection serious infection ( opinion investigator ) within 6 month prior screen Any follow within 21 day randomization study : Clinically significant active infection , include ongoing , chronic infection Any infection require hospitalization treatment IV antiinfectives Completion course oral antiinfectives within 14 day randomization study Any acute illness evidence clinically significant active infection , fever ≥ 38.0 degree C ( ≥ 100.5 degree F ) screen Day 1 Evidence active tuberculosis ( TB ) , either treat untreated , latent TB without completion appropriate course treatment appropriate ongoing prophylactic treatment . Evaluation treatment accord local standard care may consist history physical examination , and/or chest X ray , and/or TB test ( eg . purify protein derivative ) testing , standard care determine local guideline History primary immunodeficiency underlie condition predisposes subject infection ( eg , splenectomy ) Receipt live attenuate vaccine within 21 day randomization study anticipate give within 5 halflives last dose investigational product administration , halflife estimate approximately 15 day . Therefore , receipt live attenuate vaccine avoid 75 day post dose investigational product Medically indicate adult immunization current ( eg , pneumococcal vaccine ) Current evidence alcohol , drug chemical abuse , recent history abuse &lt; 1 year prior randomization study History cancer except basal cell carcinoma treat apparent success curative therapy ≥ 1 year prior randomization study Major surgery within 8 week randomization study elective surgery plan screen Early Discontinuation Visit/End Study ( Day 85 , singledose cohort ) History disease , evidence current disease ( scleroderma ) , find upon physical examination , chest xray , laboratory abnormality , opinion investigator medical monitor , may compromise safety subject study confound analysis study Any institutionalize individual Employees clinical study site individual involve conduct study , immediate family member individual Concurrent enrollment another clinical study exception observational interventional study involve therapeutic strategy invasive diagnostic test Concurrent enrollment another clinical study investigational product administer within 4 week prior Day 1 within 5 halflives investigational product , whichever long Known sensitivity acetaminophen/paracetamol , diphenhydramine , methylprednisolone equivalent glucocorticoid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>